BioSpace News Archive

Drug Development

Astex Announces That the Phase 3 ASCERTAIN - Acute Myeloid Leukemia (AML) Clinical Study of Oral Hypomethylating Agent Decitabine and Cedazuridine Fixed-Dose Combination (ASTX727 or DEC-C) Met the Trial’s Primary Endpoint

Astex Pharmaceuticals, Inc. announces today top-line results from the ASCERTAIN phase 3 study evaluating oral decitabine and cedazuridine fixed-dose combination (ASTX727 or DEC-C) tablets versus IV decitabine in adults with AML who are not candidates to receive standard induction chemotherapy.

May 12, 2022
·
13 min read
Business

Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights

Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the first quarter ended March 31, 2022.

May 12, 2022
·
11 min read
Drug Development

Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates

Athira Pharma, Inc. announced the company’s financial results for the quarter ended March 31, 2022 and provided pipeline and business updates.

May 12, 2022
·
14 min read
Business

Adverum Biotechnologies Reports First Quarter 2022 Financial Results

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, reported financial results for the first quarter ended March 31, 2022.

May 12, 2022
·
9 min read
Business

Sigilon Therapeutics Reports First Quarter 2022 Financial Results And Business Highlights

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, reported financial results for the first quarter ended March 31, 2022 as well as certain other business highlights.

May 12, 2022
·
9 min read
Business

Eyenovia Reports First Quarter 2022 Financial Results

Eyenovia, Inc., a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print platform technology, announced its financial and operating results for the first quarter ended March 31, 2022.

May 12, 2022
·
11 min read
Business

KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates

KemPharm, Inc., a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system and neurodegenerative diseases, reported its financial results for the first quarter ended March 31, 2022.

May 12, 2022
·
12 min read
Business

Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update

Talaris Therapeutics, Inc. reported financial results for the three-month period ended March 31, 2022, and provided an update on its business.

May 12, 2022
·
8 min read
Business

Acutus Medical Reports First Quarter 2022 Financial Results and CEO Transition

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, reported results for the first quarter of 2022 and announced a leadership transition.

May 12, 2022
·
14 min read
Business

Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update

Brickell Biotech, Inc. announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.

May 12, 2022
·
12 min read